Proteomics in Small Cell Lung Cancer
ConditionSmall Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorAalborg University Hospital
About this trial
The aim of this study is to gather insight into tumor-derived circulating extracellular vesicles-proteins in patients with newly diagnosed small cell lung cancer.
Eligibility criteria
This trial accepts healthy volunteersQualifiers
Written and signed informed consent
Histopathologically and/or cytologically newly-diagnosed SCLC
Measurable disease on CT scans
Eligibility to receive standard chemotherapy consisting of carboplatin and etoposide
Disqualifiers
Active biopsy-verified second malignancy other than non-melanoma skin cancer or cervical carcinoma in situ
Prior treatment for any malignant diseases other than non-melanoma skin cancer and cervical carcinoma in situ
Concomitant anticoagulation treatment (acetylsalicylic acid and clopidogrel are allowed)
Treatment with any other investigational agent
Trial population
The study will include 50 patients with newly diagnosed SCLC, referred to systemic antineoplastic treatment at the Dept. of Oncology, Aalborg University Hospital.
Trial design
Design model
Case-control
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Identification and validation of protein biomarkers
For identification and validation of protein biomarkers both untargeted and targeted proteomics will be performed, including a discovery-based bottom-up mass spectrometry approach and label-free Quantification Nano Liquid Chromatography Tandem Mass Spectrometry (LFQ nLC-MS/MS), enzyme-linked immunosorbent assay (ELISA)-based proteomics, and Western Blot analyses.
Time frame
3 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov